Literature DB >> 34001222

Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS.

Luis Morales-Quinteros1,2,3, Ary Serpa Neto4,5,6,7, Antonio Artigas8,9,10,11, Lluis Blanch8,9,10,11, Michela Botta4, David A Kaufman12, Marcus J Schultz4,13,14, Anissa M Tsonas4, Frederique Paulus4, Lieuwe D Bos4.   

Abstract

BACKGROUND: Estimates for dead space ventilation have been shown to be independently associated with an increased risk of mortality in the acute respiratory distress syndrome and small case series of COVID-19-related ARDS.
METHODS: Secondary analysis from the PRoVENT-COVID study. The PRoVENT-COVID is a national, multicenter, retrospective observational study done at 22 intensive care units in the Netherlands. Consecutive patients aged at least 18 years were eligible for participation if they had received invasive ventilation for COVID-19 at a participating ICU during the first month of the national outbreak in the Netherlands. The aim was to quantify the dynamics and determine the prognostic value of surrogate markers of wasted ventilation in patients with COVID-19-related ARDS.
RESULTS: A total of 927 consecutive patients admitted with COVID-19-related ARDS were included in this study. Estimations of wasted ventilation such as the estimated dead space fraction (by Harris-Benedict and direct method) and ventilatory ratio were significantly higher in non-survivors than survivors at baseline and during the following days of mechanical ventilation (p < 0.001). The end-tidal-to-arterial PCO2 ratio was lower in non-survivors than in survivors (p < 0.001). As ARDS severity increased, mortality increased with successive tertiles of dead space fraction by Harris-Benedict and by direct estimation, and with an increase in the VR. The same trend was observed with decreased levels in the tertiles for the end-tidal-to-arterial PCO2 ratio. After adjustment for a base risk model that included chronic comorbidities and ventilation- and oxygenation-parameters, none of the dead space estimates measured at the start of ventilation or the following days were significantly associated with 28-day mortality.
CONCLUSIONS: There is significant impairment of ventilation in the early course of COVID-19-related ARDS but quantification of this impairment does not add prognostic information when added to a baseline risk model. TRIAL REGISTRATION: ISRCTN04346342. Registered 15 April 2020. Retrospectively registered.

Entities:  

Keywords:  ARDS; Acute respiratory distress syndrome; COVID-19; Dead space; Mortality; Prognostication; Respiratory dead space; Ventilatory ratio

Year:  2021        PMID: 34001222     DOI: 10.1186/s13054-021-03570-0

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


  2 in total

1.  Prognostic value of the pulmonary dead-space fraction during the early and intermediate phases of acute respiratory distress syndrome.

Authors:  Joan M Raurich; Margalida Vilar; Asunción Colomar; Jordi Ibáñez; Ignacio Ayestarán; Jon Pérez-Bárcena; Juan A Llompart-Pou
Journal:  Respir Care       Date:  2010-03       Impact factor: 2.258

2.  Prognostic value of the pulmonary dead-space fraction during the first 6 days of acute respiratory distress syndrome.

Authors:  Richard H Kallet; James A Alonso; Jean-François Pittet; Michael A Matthay
Journal:  Respir Care       Date:  2004-09       Impact factor: 2.258

  2 in total
  5 in total

1.  Increased respiratory dead space could associate with coagulation activation and poor outcomes in COVID-19 ARDS.

Authors:  Jerónimo Graf; Rodrigo Pérez; René López
Journal:  J Crit Care       Date:  2022-06-17       Impact factor: 4.298

2.  Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids.

Authors:  Pratik Sinha; David Furfaro; Matthew J Cummings; Darryl Abrams; Kevin Delucchi; Manoj V Maddali; June He; Alison Thompson; Michael Murn; John Fountain; Amanda Rosen; Shelief Y Robbins-Juarez; Matthew A Adan; Tejus Satish; Mahesh Madhavan; Aakriti Gupta; Alexander K Lyashchenko; Cara Agerstrand; Natalie H Yip; Kristin M Burkart; Jeremy R Beitler; Matthew R Baldwin; Carolyn S Calfee; Daniel Brodie; Max R O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

3.  Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study.

Authors:  Pedro David Wendel-Garcia; Jordi Mancebo; Arantxa Mas; Cristina González-Isern; Ricard Ferrer; Rafael Máñez; Joan-Ramon Masclans; Elena Sandoval; Paula Vera; Josep Trenado; Rafael Fernández; Josep-Maria Sirvent; Melcior Martínez; Mercedes Ibarz; Pau Garro; José Luis Lopera; María Bodí; Joan Carles Yébenes-Reyes; Carles Triginer; Imma Vallverdú; Anna Baró; Fernanda Bodí; Paula Saludes; Mauricio Valencia; Ferran Roche-Campo; Arturo Huerta; Francisco José Cambra; Carme Barberà; Jorge Echevarria; Óscar Peñuelas
Journal:  Crit Care       Date:  2022-02-08       Impact factor: 9.097

Review 4.  Myths and Misconceptions of Airway Pressure Release Ventilation: Getting Past the Noise and on to the Signal.

Authors:  Penny Andrews; Joseph Shiber; Maria Madden; Gary F Nieman; Luigi Camporota; Nader M Habashi
Journal:  Front Physiol       Date:  2022-07-25       Impact factor: 4.755

5.  The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial.

Authors:  Ana Carolina Costa Monteiro; Sitaram Vangala; Katherine D Wick; Kevin L Delucchi; Emily R Siegel; B Taylor Thompson; Kathleen D Liu; Anil Sapru; Pratik Sinha; Michael A Matthay
Journal:  Crit Care       Date:  2022-09-29       Impact factor: 19.334

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.